Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks.

Trial Profile

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2014

At a glance

  • Drugs Citalopram/pipamperone (Primary) ; Citalopram; Pipamperone
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaNeuroBoost
  • Most Recent Events

    • 18 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrilas.gov record.
    • 03 Jul 2013 Trial protocol presented at APA 2013.
    • 13 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top